PCSK9 - Wikipedia
PCSK9 has medical importance because it acts in lipoprotein homeostasis. Agents that block PCSK9 can lower LDL particle concentrations.
PCSK9 Inhibitors: How They Manage Cholesterol and Side Effects
What are PCSK9 inhibitors? PCSK9 inhibitors are a type of cholesterol-lowering drug. They reduce your low-density lipoprotein (LDL) cholesterol or “bad” cholesterol. This medication may be especially …
PCSK9 Inhibitors: A Full List, Side Effects, and More - Healthline
Sep 9, 2025 · PCSK9 inhibitors are an injectable treatment for high LDL cholesterol that may provide a safe alternative for people who can’t take statins or who have genetic conditions that increase the risk...
PCSK9 inhibitors: Pharmacology, adverse effects, and use
Jan 15, 2026 · PCSK9 inhibitors have been approved by regulatory agencies for the treatment of individuals with inadequately treated levels of LDL-cholesterol (LDL-C). They are capable of lowering …
What Is PCSK9 and How Does It Affect Cholesterol?
2 days ago · PCSK9 is a protein your liver makes that controls how much cholesterol stays in your bloodstream. Its full name, proprotein convertase subtilisin/kexin type 9, rarely comes up outside a …
List of PCSK9 inhibitors - Drugs.com
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme that binds to low-density lipoprotein receptors (LDL receptors), which stops LDL being removed from the blood, leading to an increase in …
Adding a PCSK9-i to statin therapy has been shown to reduce LDL-C, arterial plaque, and cardiovascular events in research studies. Typically, PCSK9-i lower LDL-C by an additional 45-64% …
How Do PCSK9 Inhibitors Lower Cholesterol? - WebMD
Nov 15, 2024 · PCSK9 inhibitors are a new class of drugs that lower LDL, or “bad,” cholesterol. Right now, there are two FDA-approved medications: alirocumab (Praluent) and evolocumab (Repatha).
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
Feb 4, 2026 · Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; …
PCSK9 function and physiology - PMC
By infusing recombinant human PCSK9 into mice, they established that the levels of PCSK9 found in human plasma are indeed sufficient to reduce hepatic LDL receptors.